RT Journal Article
SR Electronic
T1 Imaging Calreticulin for Early Detection of Immunogenic Cell Death During Anticancer Treatment
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 956
OP 960
DO 10.2967/jnumed.120.245290
VO 62
IS 7
A1 Kim, Dong-Yeon
A1 Pyo, Ayoung
A1 Yun, Misun
A1 Thangam, Ramar
A1 You, Sung-Hwan
A1 Zhang, Ying
A1 Jung, Ye-rim
A1 Nguyen, Dinh-Huy
A1 Venu, Akhil
A1 Kim, Hyeon Sik
A1 Yoon, Mee Sun
A1 Hong, Yeongjin
A1 Min, Jung-Joon
YR 2021
UL http://jnm.snmjournals.org/content/62/7/956.abstract
AB Surface-exposed calreticulin (ecto-CRT) is a well-known “eat-me” signal exhibited by dying cells that contributes to their recognition and destruction by the immune system. We assessed the use of a CRT-specific binding peptide for imaging ecto-CRT during immunogenic cell death and its utility for early prediction of treatment response. Methods: A synthetic CRT-specific peptide, KLGFFKR (CRTpep), was labeled with fluorescein isothiocyanate or 18F, and the characteristics of ecto-CRT were evaluated in a colon cancer cell line in vitro and in vivo. Results: In vitro flow cytometry, immunofluorescence staining, and in vivo small-animal PET imaging results showed that CRTpep detected preapoptotic cells treated with immunogenic drugs or radiation but not those treated with the nonimmunogenic drug or a nontherapeutic dose of immunogenic drug. Conclusion: The present results indicate that the CRT-specific peptide would enable the prediction of therapeutic response, thereby facilitating early decisions on continuation or discontinuation of immunogenic treatment.